SOURCE: Cutting Edge Information

Cutting Edge Information Home

June 22, 2017 15:41 ET

Centralized Adaptive Trial Design Teams Facilitate Communication Between Global & Country-Level Pharma Teams

65% of surveyed global life science teams have a centralized adaptive trial reporting structure

RESEARCH TRIANGLE PARK, NC--(Marketwired - June 22, 2017) - The majority of surveyed clinical trial teams -- from those with global responsibility to those positioned at the country level -- report better cross-geography communication through centralized adaptive trial design decision-making structures, according to a recent study by business intelligence firm Cutting Edge Information.

The study, Adaptive Design Clinical Trials: Strategically Modify Traditional Methodologies to Support Efficient Clinical Operations, found that 65% of surveyed global teams have a centralized adaptive trial reporting structure. In these structures, global teams develop strategy and allow country-level teams to adjust the strategy to better align with any specific needs they may have. Additionally, half of surveyed non-global teams with either therapeutic or regional responsibility also report centralized structures.

Of the organizations that are not completely centralized, most (30%) have at least some degree of centralization in place. The remaining 5% of surveyed clinical teams report a decentralized structure.

"Establishing centralized clinical structures helps influence active dialogue between global and country-level teams," says Adam Bianchi, senior director of research at Cutting Edge Information. "Because they foster open communication, various company types tend to favor centralized adaptive design structures."

The data show that company type affects the degree of centralization that the organization uses. Both surveyed teams at Top 10 pharmaceutical organizations report using somewhat centralized clinical structures.

By comparison, each of the four surveyed Top 50 company teams leverage completely centralized structures. The key difference between centralized and somewhat centralized structures is that in the former, non-global teams do not contribute to clinical strategy development.

The only company who reported a completely decentralized decision-making process was a small pharmaceutical firm. When decision making is completely decentralized, country-level clinical teams make their own decisions about the use of adaptive trial design, depending on specific trial needs.

Adaptive Design Clinical Trials: Strategically Modify Traditional Methodologies to Support Efficient Clinical Operations, available at https://www.cuttingedgeinfo.com/product/adaptive-design-clinical-trials/, details the time- and cost-savings metrics associated with adaptive design clinical trials. This report covers the industry's use of adaptive trial design including organizational structures, resources and uses of adaptive designs across specific trial development stages and therapeutic areas.

The study also includes:

  • Cost-per-patient benchmarks for early- and late-stage adaptive and non-adaptive trials
  • Metrics tracking cross-functional involvement in adaptive trial design
  • Ratios of adaptive vs. non-adaptive clinical studies across 11 therapeutic areas
  • Real-world profiles illustrating how life sciences teams are using adaptive design
  • Analysis of adaptive trial design planning and execution challenges and solutions

To see a list of Cutting Edge Information's clinical development industry research studies, please visit: https://www.cuttingedgeinfo.com/product-category/clinical-development/.

Image Available: http://www.marketwire.com/library/MwGo/2017/6/21/11G141599/Images/mw1bj60d7m181ashe1b4te6v16ae2-89732d074d32b064be897cb3fbe1e39f.jpg

Contact Information